These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29961686)

  • 1. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
    Bharucha KN; Brunner HI; Calvo Penadés I; Nikishina I; Rubio-Pérez N; Oliveira S; Kobusinska K; Schmeling H; Sztajnbok F; Weller-Heinemann F; Zholobova E; Zulian F; Allen R; Chaitow J; Frane J; Wells C; Ruperto N; De Benedetti F;
    J Rheumatol; 2018 Aug; 45(8):1173-1179. PubMed ID: 29961686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial.
    De Benedetti F; Brunner H; Ruperto N; Schneider R; Xavier R; Allen R; Brown DE; Chaitow J; Pardeo M; Espada G; Gerloni V; Myones BL; Frane JW; Wang J; Lipman TH; Bharucha KN; Martini A; Lovell D;
    Arthritis Rheumatol; 2015 Mar; 67(3):840-8. PubMed ID: 25504861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
    Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    Pardeo M; Wang J; Ruperto N; Alexeeva E; Chasnyk V; Schneider R; Horneff G; Huppertz HI; Minden K; Onel K; Zemel L; Martin A; Koné-Paut I; Siamopoulou-Mavridou A; Silva CA; Porter-Brown B; Bharucha KN; Brunner HI; De Benedetti F;
    J Rheumatol; 2019 Sep; 46(9):1117-1126. PubMed ID: 30824645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI; Chen C; Bovis F; De Benedetti F; Espada G; Joos R; Akikusa J; Chaitow J; Boteanu AL; Kimura Y; Rietschel C; Siri D; Smolewska E; Schmeling H; Brown DE; Martini A; Lovell DJ; Huang B; Ruperto N;
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1264-1274. PubMed ID: 32702212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
    Miyamae T; Yokoya S; Yamanaka H; Yokota S
    Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C; Tang X; Zhou Z; Sun L; Lu M; Zhou W; Yang S; Zheng W; Yu H; Tan W; Zhang J; Zhang Y; Kong Y; Xu J
    Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
    Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI; Ruperto N; Ramanan AV; Horneff G; Minden K; Calvo Penades I; Alexeeva E; Cleary G; Stern SM; Kone-Paut I; Maldonado Velázquez MDR; Rabinovich CE; Remesal A; Silva CA; Nikishina I; Zucchetto M; Brockwell L; Gordon O; Nagel S; De Benedetti F;
    Rheumatology (Oxford); 2024 Sep; 63(9):2535-2546. PubMed ID: 38552315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials.
    Malattia C; Ruperto N; Pederzoli S; Palmisani E; Pistorio A; Wouters C; Dolezalova P; Flato B; Garay S; Giancane G; Wells C; Douglass W; Brunner HI; De Benedetti F; Ravelli A;
    Arthritis Res Ther; 2020 Sep; 22(1):211. PubMed ID: 32912276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
    De Benedetti F; Brunner HI; Ruperto N; Kenwright A; Wright S; Calvo I; Cuttica R; Ravelli A; Schneider R; Woo P; Wouters C; Xavier R; Zemel L; Baildam E; Burgos-Vargas R; Dolezalova P; Garay SM; Merino R; Joos R; Grom A; Wulffraat N; Zuber Z; Zulian F; Lovell D; Martini A; ;
    N Engl J Med; 2012 Dec; 367(25):2385-95. PubMed ID: 23252525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Zhang X; Chen YC; Terao K
    Expert Rev Clin Pharmacol; 2017 May; 10(5):471-482. PubMed ID: 28293968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.